AstraZeneca and Daiichi Sankyo’s Enhertu plus Roche’s Perjeta demonstrated the potential to shake up first-line treatment of ...

South Korean biotech Curogen plans US expansion, adds COO Arvind Sood and board members as it preps for first clinical trial ...

Self-described “blunt pharma executives,” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News ...

Kymera Therapeutics reports positive Phase 1 data for oral drug KT-621, targeting STAT6 as potential competitor to ...

BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker ...

Vera Therapeutics’ rare kidney disease candidate atacicept appears to have pulled off an unusual trick: being more effective ...

Zetagen Therapeutics, founded 2015, private clinical-stage biopharmaceutical company develops first-of-its-kind targeted ...

Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease ...

AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects ...

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of ...